{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"}],"units":"Participants"}],"title":"Relapse Within 6 Months of Last Relapse"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"}],"units":"Participants"}],"title":"ISS Disease Stage I"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"}],"units":"Participants"}],"title":"ISS Disease Stage II"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"}],"units":"Participants"}],"title":"ISS Disease Stage III"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"}],"units":"Participants"}],"title":"CRAB Signs, None"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"}],"units":"Participants"}],"title":"CRAB Signs, Some-Increase in blood calcium levels"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"}],"units":"Participants"}],"title":"CRAB Signs, Some-Renal Failure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"}],"units":"Participants"}],"title":"CRAB Signs, Some-Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"}],"units":"Participants"}],"title":"CRAB Signs, Some-Bone lesions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"Cytogenetic Abnormalities, t(4;14)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"Cytogenetic Abnormalities, t(11;14)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"Cytogenetic Abnormalities, t(14;16)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"Cytogenetic Abnormalities, Trisomies"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"Cytogenetic Abnormalities, d (17p)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"Cytogenetic Abnormalities, g (1q)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"Cytogenetic Abnormalities, other"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"title":"Risk, High"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"title":"Risk, Standard"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"title":"Risk, Intermediate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"272"}],"units":"Participants"}],"title":"Diffuse osteopathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"}],"units":"Participants"}],"title":"Fractures"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"}],"units":"Participants"}],"title":"Neurological symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"}],"units":"Participants"}],"title":"Infections"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"title":"Comorbidities, Diabetes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"title":"Comorbidities, Neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"title":"Comorbidities, Nephropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"title":"Comorbidity, COPD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"title":"Comorbidities, Cardiovascular disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"title":"Comorbidities, Liver failure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"title":"Comorbidities,Psychiatric or Neurological Disorder"},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"title":"Comorbidities, Other secondary disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"}],"units":"Participants"}],"title":"Medullary Plasmacytoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"}],"units":"Participants"}],"title":"Extramedullary Plasmacytoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"}],"units":"Participants"}],"title":"Anti-CD38 mAb Monotherapy, Second Line"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"Anti-CD38 mAb Monotherapy, Third Line"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"title":"Anti-CD38 mAb Monotherapy, Fourth Line or Later"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"}],"units":"Participants"}],"title":"Double PI Therapy+Steroids/Alkylating Agent,2 Line"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"Double PI therapy+Steroids/Alkylating Agent,3 Line"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"title":"DoublePI Therapy+Steroids/Alkylating Agent,>=4Line"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"}],"units":"Participants"}],"title":"Autologous transplant, Second Line"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"title":"Autologous transplant, Third Line"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Autologous transplant, Fourth Line or Later"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"}],"units":"Participants"}],"title":"Allogeneic transplant, Second Line"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"title":"Allogeneic transplant, Third Line"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Allogeneic transplant, Fourth Line or Later"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"}],"units":"Participants"}],"title":"Autologous or Allogeneic Transplant, Second Line"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"title":"Autologous or Allogeneic Transplant, Third Line"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Autologous or Allogeneic Transplant, >=4 Lines"}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"}],"units":"Participants"}],"description":"Clinical variables include date of latest symptomatic relapse and/or refractory episode, ISS disease stage, CRAB signs, other clinical variables (plasmacytomas: medullary or extramedullary, diffuse osteopenia, fractures, neurological symptoms, infections, concomitant diseases like diabetes, neuropathy, chronic obstructive pulmonary disease (COPD), cardiovascular disease, liver failure, psychiatric and/or neurological disorders, any other secondary disorders, cytogenetic abnormalities, risk according to cytogenetic profile at relapse(standard:trisomies,t\\[11;14\\];t\\[6;14\\],intermediate:t\\[4;14\\],g\\[1q\\], high:d\\[17p\\],t\\[14;16\\],t\\[14;20\\],other), treatment started after latest symptomatic relapse and/or refractory episode.","groups":[{"description":"Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.","id":"OG000","title":"Multiple Myeloma (MM) Participants"}],"paramType":"NUMBER","populationDescription":"All participants eligible for analyses were included. Number analyzed is the number of participants with data available for analyses for the specific category. Participants are repeated across multiple categories. Percentages were rounded off.","reportingStatus":"POSTED","timeFrame":"Day 1","title":"Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode","type":"PRIMARY","unitOfMeasure":"percentage of participants"}